c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
## c-Met/HGFR Inhibitors & Activators

### 2-Phospho-L-ascorbic acid trisodium salt (L-Ascorbic acid 2-phosphate trisodium salt; ...) Cat. No.: HY-107837

2-Phospho-L-ascorbic acid trisodium salt acts as an antioxidant and a stimulator of hepatocyte growth factor (HGF) production.

*Purity:* 99.36%
*Clinical Data:* No Development Reported
*Size:* 10 mM × 1 mL, 500 mg, 1 g

### AMG-208 Cat. No.: HY-12035

AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. IC50 value: 9.3 nM Target: c-Met in vitro: AMG-208 shows the potent inhibition of kinase c-Met activity with IC50 of 9 nM in a cell-free assay.

*Purity:* 99.34%
*Clinical Data:* Phase 2
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib (MP470; HPK 56) Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.

*Purity:* 99.36%
*Clinical Data:* Phase 2
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### BMS 777607 (BMS 817378) Cat. No.: HY-12076

BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all...

*Purity:* 99.48%
*Clinical Data:* Phase 2
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### BMS-794833 Cat. No.: HY-10497

BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50s of 15 and 1.7 nM, respectively.

*Purity:* 99.82%
*Clinical Data:* No Development Reported
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Altiratinib (DCC-2701) Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.

*Purity:* 95.95%
*Clinical Data:* Phase 1
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### AMG-337 Cat. No.: HY-18696

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5 nM in enzymatic assays.

*Purity:* 99.36%
*Clinical Data:* Phase 2
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

### Amuvatinib hydrochloride (MP470 hydrochloride; HPK 56 hydrochloride) Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.

*Purity:* > 98%
*Clinical Data:* No Development Reported
*Size:* 5 mg, 10 mg, 50 mg, 100 mg

### BMS-193871 (ALT-101) Cat. No.: HY-125017

BMS-193871 is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. BMS-193871 is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

*Purity:* > 98%
*Clinical Data:* Phase 2
*Size:* 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
**BPI-9016M**

Cat. No.: HY-114356

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

**c-Kit-IN-1**

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC\(_{50}\)s of <200 nM.

Purity: 98.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**c-Met inhibitor 1**

Cat. No.: HY-15735

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**c-Met-IN-1**

Cat. No.: HY-101031

c-Met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC\(_{50}\) of 1.1 nM, with antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

---

**c-Met-IN-2**

Cat. No.: HY-101773

c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC\(_{50}\) of 0.6 nM, with antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

---

**Capmatinib**

(Cat. No.: HY-13404)

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC\(_{50}\)=0.13 nM).

Purity: 99.84%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

**CEP-40783**

(Cat. No.: HY-100946)

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC\(_{50}\) values of 7 nM and 12 nM, respectively.

Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Crizotinib**

(PF-02341066)

Crizotinib (PF-02341066) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC\(_{50}\)s of 20 and 8 nM, respectively.

Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**Crizotinib hydrochloride**

(PF-02341066 hydrochloride)

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC\(_{50}\)s of 20 and 8 nM, respectively.

Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF1R-IN-2</td>
<td>HY-111787</td>
<td>CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC₅₀ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.</td>
</tr>
<tr>
<td>EGFR-IN-8</td>
<td>HY-126320</td>
<td>EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.</td>
</tr>
<tr>
<td>Ensartinib hydrochloride (X-396 hydrochloride)</td>
<td>HY-103714A</td>
<td>Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC₅₀ of &lt;0.4 nM and 0.74 nM, respectively.</td>
</tr>
<tr>
<td>Glesatinib hydrochloride (MGCD265 hydrochloride)</td>
<td>HY-19642A</td>
<td>Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.</td>
</tr>
<tr>
<td>Glumetinib (SCC244)</td>
<td>HY-116000</td>
<td>Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC₅₀ of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.</td>
</tr>
<tr>
<td>Golovatinib (E-7050)</td>
<td>HY-13068</td>
<td>Golovatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC₅₀ of 14 and 16 nM, respectively.</td>
</tr>
<tr>
<td>JNJ-38877605</td>
<td>HY-50683</td>
<td>JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</td>
</tr>
</tbody>
</table>
JNJ-38877618  
Cat. No.: HY-111050

JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC_{50} of 2 and 3 nM for wild type and mutant Met, respectively.

Purity: 99.01%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Meleagrin  
Cat. No.: HY-N6797

Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg

Merestinib  (LY2801653)  
Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (K_{i}=2 nM) with anti-tumor activities.

Purity: 99.99%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride  (LY2801653 dihydrochloride)  
Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (K_{i}=2 nM) with anti-tumor activities.

Purity: 99.02%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MGCD-265 analog  
Cat. No.: HY-10991

MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.

Purity: 96.53%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MK-2461  
Cat. No.: HY-50703

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.

Purity: 99.92%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

MK-8033  
Cat. No.: HY-13299

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC_{50}=1 nM Wt c-Met) under investigation as a treatment for cancer.

Purity: >98.0%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-8033 hydrochloride  
Cat. No.: HY-13299A

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC_{50}=1 nM Wt c-Met) under investigation as a treatment for cancer.

Purity: >98%  
Clinical Data: Phase 1  
Size: 5 mg, 10 mg, 50 mg

Ningetinib  
Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC_{50} of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 98.75%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate  
Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC_{50} of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 99.88%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
### NPS-1034
**Cat. No.:** HY-100509  
NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀ values of 10.3 and 48 nM, respectively.  
Purity: >98.0%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### NVP-BVU972
**Cat. No.:** HY-15456  
NVP-BVU972 is a selective and potent Met inhibitor (IC₅₀ = 14 nM). Antitumor agents.  
Purity: 97.35%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### PF-04217903
**Cat. No.:** HY-12017  
PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC₅₀ of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).  
Purity: 99.64%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### PF-04217903 methanesulfonate
**Cat. No.:** HY-12017A  
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC₅₀ of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).  
Purity: 99.87%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### PHA-665752
**Cat. No.:** HY-11107  
PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase (Kᵣ=4 nM; IC₅₀=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.  
Purity: 99.09%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### S49076
**Cat. No.:** HY-12965  
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC₅₀ values below 20 nM.  
Purity: 98.62%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

### SAR125844
**Cat. No.:** HY-16446  
SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC₅₀ of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.  
Purity: 99.03%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Savolitinib
**Cat. No.:** HY-15959  
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC₅₀ of 5 nM and 3 nM for c-Met and p-Met, respectively.  
Purity: 98.45%  
Clinical Data: Phase 3  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

### SGX-523
**Cat. No.:** HY-12019  
SGX-523 is a selective Met inhibitor with IC₅₀ of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC₅₀ value: 4 nM Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGF/RTK) tyrosine kinase inhibitors.  
Purity: >98.0%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
SRI 31215 TFA  
**Cat. No.: HY-114363A**

SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC₅₀ of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.

**Purity:** 99.06%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

SU11274  
**(PKI-SU11274)**  
**Cat. No.: HY-12014**

SU11274 is a selective Met inhibitor with IC₅₀ of 10 nM, but has no effects on PDGFRβ, EGFR or Tie2.

**Purity:** 98.09%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

---

TAS-115  
**Cat. No.: HY-12423**

TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC₅₀ of 30 and 32 nM for rVEGFR2 and rMET, respectively.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg, 20 mg

---

TAS-115 mesylate  
**(TAS-115 methanesulfonate)**  
**Cat. No.: HY-12423A**

TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC₅₀ of 30 and 32 nM for rVEGFR2 and rMET, respectively.

**Purity:** 99.15%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

Tepotinib  
**(EMD-1214063)**  
**Cat. No.: HY-14721**

Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC₅₀ of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

**Purity:** 99.87%  
**Clinical Data:** Phase 2  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

Tivantinib  
**(ARQ 197)**  
**Cat. No.: HY-50686**

Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with Kᵢ of 355 nM.

**Purity:** 99.39%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

Tyrosine kinase inhibitor  
**Cat. No.: HY-10421**

A Tyrosine kinase inhibitor.

**Purity:** 99.36%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

---

X-376  
**Cat. No.: HY-16590**

X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC₅₀=0.61 nM). X-376 is a less potent inhibitor of MET (IC₅₀=0.69 nM). X-376 displays potent anti-tumor activity.

**Purity:** 98.36%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

www.MedChemExpress.com